For research use only. Not for therapeutic Use.
PAWI-2 is an inhibitor which targets both Wnt signaling (IC50 value of 11 nM) and ATM/p53 (EC50 value of 1.9 nM for p53). PAWI-2 binds tubulin and potently activates mitotic stress signaling to stabilize p53 and inhibit Wnt/β-catenin transactivation of downstream genes in colorectal cancer cells. Moreover, PAWI-2 inhibits cellular proliferation of androgen-sensitive and androgen-insensitive cells (LNCaP and PC-3, respectively).
KEYWORDS: PAWI-2 | supplier | Wnt/ATM/p53 inhibitor | PAWI2 | PAWI 2 | CAS [1448427-02-8] | ECM-adhesion | β-Catenin | Wnt | Inhibitor | Proteins | Prostate cancer | ATM
Catalog Number | I047648 |
CAS Number | 1448427-02-8 |
Molecular Formula | C19H21N3O3S |
Purity | ≥95% |
IUPAC Name | 1-[4-[(4-methyl-2,3-dihydroquinoxalin-1-yl)sulfonyl]phenyl]pyrrolidin-2-one |
InChI | InChI=1S/C19H21N3O3S/c1-20-13-14-22(18-6-3-2-5-17(18)20)26(24,25)16-10-8-15(9-11-16)21-12-4-7-19(21)23/h2-3,5-6,8-11H,4,7,12-14H2,1H3 |
SMILES | CN1CCN(C2=CC=CC=C21)S(=O)(=O)C3=CC=C(C=C3)N4CCCC4=O |
Reference | J Cheng et al. A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer. J Pharmacol Exp Ther. 2019 Dec;371(3):703-712. J Cheng et al. A Novel Inhibitor Targets Both Wnt Signaling and ATM/p53 in Colorectal Cancer. Cancer Res. 2018;78(17):5072-5083. |